Hims Hers Health Inc (HIMS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Hims Hers Health Inc stock (HIMS) is currently trading at $20.84. Hims Hers Health Inc PE ratio is 41.84. Hims Hers Health Inc PS ratio (Price-to-Sales) is 2.07. Analyst consensus price target for HIMS is $24.31. WallStSmart rates HIMS as Underperform.
Hims Hers Health Inc (HIMS) stock price prediction for 2030: Base case $37.99. Bull case $47.49. Bear case $28.49. See full HIMS 2030 price forecast and methodology on WallStSmart.
- HIMS PE ratio analysis and historical PE chart
- HIMS PS ratio (Price-to-Sales) history and trend
- HIMS intrinsic value — DCF, Graham Number, EPV models
- HIMS stock price prediction 2025 2026 2027 2028 2029 2030
- HIMS fair value vs current price
- HIMS insider transactions and insider buying
- Is HIMS undervalued or overvalued?
- Hims Hers Health Inc financial analysis — revenue, earnings, cash flow
- HIMS Piotroski F-Score and Altman Z-Score
- HIMS analyst price target and Smart Rating
Hims Hers Health Inc
📊 No data available
Try selecting a different time range
HIMS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Hims Hers Health Inc (HIMS)
HIMS trades 539% above its Graham fair value of $3.47, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Hims Hers Health Inc (HIMS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, revenue growth, institutional own.. Concerns around operating margin and price/book. Mixed signals suggest waiting for clearer direction before acting.
Hims Hers Health Inc (HIMS) Key Strengths (4)
Every $100 of shareholder equity generates $25 in profit
85.78% of shares held by major funds and institutions
Strong revenue growth at 28.40% annually
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Hims Hers Health Inc (HIMS) Areas to Watch (6)
Earnings declining -17.40%, profits shrinking
Near-zero operating margins, business under pressure
Very expensive at 9.3x book value
Paying a premium for growth, expensive relative to earnings expansion
Thin profit margins with limited profitability
Revenue is fairly priced at 2.07x sales
Supporting Valuation Data
Hims Hers Health Inc (HIMS) Detailed Analysis Report
Overall Assessment
This company scores 50/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Institutional Own., Revenue Growth. Profitability is solid with Return on Equity at 25.20%. Growth metrics are encouraging with Revenue Growth at 28.40%.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Price/Book. Some valuation metrics including PEG Ratio (2.64), Price/Sales (2.07), Price/Book (9.28) suggest expensive pricing. Growth concerns include EPS Growth at -17.40%, which may limit upside. Profitability pressure is visible in Operating Margin at 2.72%, Profit Margin at 5.47%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 25.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 28.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Institutional Own.) and negatives (EPS Growth, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HIMS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HIMS's Price-to-Sales ratio of 2.07x trades 40% below its historical average of 3.45x (16th percentile). The current valuation is 82% below its historical high of 11.55x set in Nov 2019, and 105% above its historical low of 1.01x in Nov 2021. Over the past 12 months, the PS ratio has compressed from ~3.9x as trailing revenue scaled faster than the stock price.
Compare HIMS with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Hims Hers Health Inc (HIMS) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Hims Hers Health Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 2.3B with 28% growth year-over-year. Profit margins are thin at 5.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 28% YoY, reaching 2.3B. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
ROE of 25.2% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Debt-to-equity ratio of 2.34 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Margin expansion: can Hims Hers Health Inc push profit margins above 15% as the business scales?
Growth sustainability: can Hims Hers Health Inc maintain 28%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.61, so expect amplified moves relative to the broader market.
Debt management: total debt of 1.3B is significantly higher than cash (229M). Monitor refinancing risk.
Bottom Line
Hims Hers Health Inc offers an attractive blend of growth (28% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(76 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BOUGHTON, SOLEIL Chief Legal Officer | Sell | -4,651 |
Data sourced from SEC Form 4 filings
Last updated: 11:40:14 AM
About Hims Hers Health Inc(HIMS)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.